Program
nipocalimab
Also written as “Nipocalimab” and “M281”.
Its studies are mostly in Myasthenia Gravis · Sjogren's Syndrome · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Myositis, led by Johnson & Johnson.
Drug pageNipocalimab: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 2411 open or running | phase 3since Sep 18, 2019 | Jun 14, 2016 | Dec 15, 2026phase 3 · NCT05327114 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 10 earlier studies, Jun 14, 2016 to Jul 9, 2021.
- Dec 9, 2019Named nipocalimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, M281
- Jul 13, 2021Phase 1 study in HealthyNCT04973566 · 48 enrolled · Netherlands
- Aug 2, 2021Phase 2 study in Arthritis, RheumatoidNCT04991753 · 53 enrolled · United States, Germany, Poland and more
- Dec 7, 2021Phase 1 study in HealthyNCT05151692 · 30 enrolled · China
- Feb 22, 2022Phase 3 study in Myasthenia GravisNCT05265273 · 12 planned · United States, Japan, Netherlands and more
- Apr 7, 2022Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114 · 201 planned · United States, Argentina, Australia and more
- May 17, 2022Phase 2 study in MyositisNCT05379634 · 36 enrolled · United States, Canada, Czechia and more
- Jun 13, 2023Phase 3 study in Hemolytic Disease of the Fetus and NewbornNCT05912517 · 120 planned · United States, Argentina, Australia and more
- Sep 1, 2023Phase 2 study in Arthritis, RheumatoidNCT06028438 · 103 enrolled · United States, Argentina, Germany and more
- Jun 4, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06449651 · 39 planned · Belgium, Brazil, France and more
- Jul 30, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06533098 · 50 planned · United States, Austria, Belgium and more
- Dec 18, 2024Phase 3 study in Sjogren's SyndromeNCT06741969 · 655 enrolled · United States, Argentina, Austria and more
- Oct 15, 2025Phase 3 study in Myasthenia GravisNCT07217587 · 115 planned · United States, Germany, Israel and more
- Feb 23, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07438496 · 600 planned · United States, Argentina, Australia and more
- Jun 22, 2026Phase 1 study in HealthyNCT07669077 · 8 planned · United States
Ahead
- Dec 15, 2026Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114
- Feb 4, 2027Primary completion: phase 3 study in Sjogren's SyndromeNCT06741969
- Feb 16, 2027Primary completion: phase 1 study in HealthyNCT07669077
- Jun 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT05265273
TargetBeta
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 48 |
| rozanolixizumabrule | UCB | phase 4 | 23 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07669077Healthy · United States | 1 | Recruiting | Feb 16, 2027 | 8 |
| NCT07438496Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 6, 2028 | 600 |
| NCT07217587Myasthenia Gravis · United States, Germany, Israel and more | 3 | Recruiting | Sep 28, 2027 | 115 |
| NCT06741969Sjogren's Syndrome · United States, Argentina, Austria and more | 3 | Active, not recruiting | Feb 4, 2027 | 655 |
| NCT06533098Thrombocytopenia, Neonatal Alloimmune · United States, Austria, Belgium and more | 3 | Recruiting | Dec 15, 2027 | 50 |
| NCT06449651Thrombocytopenia, Neonatal Alloimmune · Belgium, Brazil, France and more | 3 | Recruiting | Dec 5, 2029 | 39 |
| NCT06028438Arthritis, Rheumatoid · United States, Argentina, Germany and more | 2 | Completed | Aug 29, 2024 | 103 |
| NCT05912517Hemolytic Disease of the Fetus and Newborn · United States, Argentina, Australia and more | 3 | Recruiting | Aug 5, 2027 | 120 |
| NCT05379634Myositis · United States, Canada, Czechia and more | 2 | Completed | Sep 4, 2025 | 36 |
| NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more | 3 | Recruiting | Dec 15, 2026 | 201 |
| NCT05265273Myasthenia Gravis · United States, Japan, Netherlands and more | 3 | Recruiting | Jun 30, 2027 | 12 |
| NCT05151692Healthy · China | 1 | Completed | Sep 9, 2022 | 30 |
| NCT04991753Arthritis, Rheumatoid · United States, Germany, Poland and more | 2 | Completed | Aug 10, 2022 | 53 |
| NCT04973566Healthy · Netherlands | 1 | Completed | May 27, 2022 | 48 |
| NCT04968912Sjogren's Syndrome · United States, France, Germany and more | 2 | Completed | Oct 23, 2023 | 163 |
| NCT04951622Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | Nov 17, 2023 | 199 |
| NCT04883619Lupus Nephritis | 2 | Withdrawn | Feb 28, 2028 | 0 |
| NCT04882878Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more | 2 | Completed | Apr 30, 2024 | 228 |
| NCT04848558Healthy · Netherlands | 1 | Completed | May 26, 2022 | 89 |
| NCT04119050Warm Autoimmune Hemolytic Anemia · United States, Brazil, China and more | 3 | Active, not recruiting | Feb 2, 2025 | 118 |
| NCT03896295Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Terminated | Dec 9, 2020 | 37 |
| NCT03842189Hemolytic Disease of the Fetus and Newborn · United States, Australia, Belgium and more | 2 | Completed | Aug 5, 2024 | 25 |
| NCT03772587Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Jun 25, 2020 | 68 |
| NCT02828046Healthy Volunteers · Netherlands | 1 | Completed | Aug 8, 2017 | 50 |
How it is read
Names in the registry
- “Nipocalimab”, 19 entries
- “M281”, 5 entries
Conditions, from the studies’ own filings
- Myasthenia Gravis, 5 studies
- Sjogren's Syndrome, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Myositis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.